My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 345

    1.

    Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria.

    Andersen S, Bröchner-Mortensen J, Parving HH; Irbesartan in Patients With Type 2 Diabetes and Microalbuminuria Study Group.

    Diabetes Care. 2003 Dec;26(12):3296-302.PMID: 14633817 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Treatment of diabetic nephropathy with angiotensin II receptor antagonist.

    Lewis EJ, Lewis JB.

    Clin Exp Nephrol. 2003 Mar;7(1):1-8. Review.PMID: 14586737 [PubMed - indexed for MEDLINE]Related articles

    3.

    Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria.

    Rossing K, Schjoedt KJ, Jensen BR, Boomsma F, Parving HH.

    Kidney Int. 2005 Sep;68(3):1190-8.PMID: 16105050 [PubMed - indexed for MEDLINE]Related articles

    4.

    Comparative effects of Irbesartan on ambulatory and office blood pressure: a substudy of ambulatory blood pressure from the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria study.

    Rossing K, Christensen PK, Andersen S, Hovind P, Hansen HP, Parving HH; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study.

    Diabetes Care. 2003 Mar;26(3):569-74.PMID: 12610003 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.

    Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group.

    N Engl J Med. 2001 Sep 20;345(12):870-8.PMID: 11565519 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Effect of three months' treatment with irbesartan on blood and pulse pressure of hypertensive type 2 diabetic patients: open, observational study in 31,793 patients.

    Strutz F, Bramlage P, Paar WD.

    Curr Med Res Opin. 2005 Sep;21(9):1433-40.PMID: 16197662 [PubMed - indexed for MEDLINE]Related articles

    7.

    [IRMA-pRAcs: irbesartan in the treatment of microalbuminuria and proteinuria in patients with type 2 diabetes and hypertension-prospective observational study involving 38,016 patients in the general practice setting]

    Lehnert H, Bramlage P, Pittrow D, Kirch W.

    MMW Fortschr Med. 2003 Oct 9;145 Suppl 3:81-7. German. PMID: 15490772 [PubMed - indexed for MEDLINE]Related articles

    8.

    [Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes]

    Parving HH, Lehnert H, Brøchner-Mortensen J, Gomis R, Andersen S, Arner P.

    Ugeskr Laeger. 2001 Oct 1;163(40):5519-24. Danish. PMID: 11601118 [PubMed - indexed for MEDLINE]Related articles

    9.

    Irbesartan reduces the albumin excretion rate in microalbuminuric type 2 diabetic patients independently of hypertension: a randomized double-blind placebo-controlled crossover study.

    Sasso FC, Carbonara O, Persico M, Iafusco D, Salvatore T, D'Ambrosio R, Torella R, Cozzolino D.

    Diabetes Care. 2002 Nov;25(11):1909-13.PMID: 12401731 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Systematic review on urine albumin testing for early detection of diabetic complications.

    Newman DJ, Mattock MB, Dawnay AB, Kerry S, McGuire A, Yaqoob M, Hitman GA, Hawke C.

    Health Technol Assess. 2005 Aug;9(30):iii-vi, xiii-163. Review.PMID: 16095545 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Course of renal function in type 2 diabetic patients with abnormalities of albumin excretion rate.

    Nosadini R, Velussi M, Brocco E, Bruseghin M, Abaterusso C, Saller A, Dalla Vestra M, Carraro A, Bortoloso E, Sambataro M, Barzon I, Frigato F, Muollo B, Chiesura-Corona M, Pacini G, Baggio B, Piarulli F, Sfriso A, Fioretto P.

    Diabetes. 2000 Mar;49(3):476-84.PMID: 10868971 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria: response to Andersen, Brochner-Mortensen, and Parving.

    Kaiser T, Florack C, Sawicki PT.

    Diabetes Care. 2004 Jun;27(6):1521; author reply 1521-2. No abstract available. PMID: 15161820 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Autoregulated glomerular filtration rate during candesartan treatment in hypertensive type 2 diabetic patients.

    Christensen PK, Lund S, Parving HH.

    Kidney Int. 2001 Oct;60(4):1435-42.PMID: 11576357 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Short-term effects of irbesartan treatment on microalbuminuria in patients with normotensive type 2 diabetes.

    Cetinkalp SS, Karadeniz MM, Erdogan MA, Ozgen GA, Yilmaz CO.

    Saudi Med J. 2008 Oct;29(10):1414-8.PMID: 18946564 [PubMed - indexed for MEDLINE]Related articles

    15.

    Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy.

    Jacobsen P, Andersen S, Rossing K, Hansen BV, Parving HH.

    Nephrol Dial Transplant. 2002 Jun;17(6):1019-24.PMID: 12032191 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    Irbesartan treatment reduces biomarkers of inflammatory activity in patients with type 2 diabetes and microalbuminuria: an IRMA 2 substudy.

    Persson F, Rossing P, Hovind P, Stehouwer CD, Schalkwijk C, Tarnow L, Parving HH.

    Diabetes. 2006 Dec;55(12):3550-5.PMID: 17130503 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: a sequential, randomized, double-blind clinical trial.

    Derosa G, Cicero AF, D'Angelo A, Fogari E, Salvadeo S, Gravina A, Ferrari I, Fassi R, Fogari R.

    Clin Ther. 2007 Apr;29(4):602-10.PMID: 17617283 [PubMed - indexed for MEDLINE]Related articles

    18.

    The Irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics. For the Collaborative Study Group.

    Rodby RA, Rohde RD, Clarke WR, Hunsicker LG, Anzalone DA, Atkins RC, Ritz E, Lewis EJ.

    Nephrol Dial Transplant. 2000 Apr;15(4):487-97.PMID: 10727543 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    Long-term renoprotection by perindopril or nifedipine in non-hypertensive patients with Type 2 diabetes and microalbuminuria.

    Jerums G, Allen TJ, Campbell DJ, Cooper ME, Gilbert RE, Hammond JJ, O'Brien RC, Raffaele J, Tsalamandris C; Melbourne Diabetic Nephropathy Study Group.

    Diabet Med. 2004 Nov;21(11):1192-9.PMID: 15498085 [PubMed - indexed for MEDLINE]Related articles

    20.

    Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study.

    Rossing K, Christensen PK, Jensen BR, Parving HH.

    Diabetes Care. 2002 Jan;25(1):95-100.PMID: 11772908 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity